Ignite Creation Date:
2024-05-06 @ 9:09 AM
Last Modification Date:
2024-10-26 @ 12:10 PM
Study NCT ID:
NCT02916810
Status:
RECRUITING
Last Update Posted:
2023-03-24
First Post:
2016-06-28
Brief Title:
TMS for Symptom Reduction in Schizophrenia
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
TMS for Symptom Reduction in Schizophrenia
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to test the hypothesis that functionally navigated repetitive TMS stimulations to the prefrontal cortex PFC modulate aberrant cortical electrical activities at PFC circuitry The TMS location of the PFC site will be individually localized by the symptom-related functional connectivity between PFC and symptom related areas such as the auditory and language processing cortex The investigators predict that such modulation will correct abnormal activities in patients with schizophrenia reduce symptoms especially auditory hallucination and improve working memorysustained attention performance
Detailed Description:
Neuroimaging studies suggest that aberrant activities at specific brain regions such as sensory areas and language-related areas are related to psychosis symptoms including auditory and visual hallucination delusion and thought disorders Transcranial magnetic stimulation TMS provides a non-invasive means for altering brain electrical neural activity TMS has been approved by FDA for treatment of depression Other applications have not been approved but it has been used in a wide range of clinical research especially in neurology and psychiatry Among psychotic symptoms there are preliminary significant improvement in treatments of auditory hallucination using TMS with small samples but those treatments are not robust in larger samples The high inter-subject variability limits the efficacy of TMS treatment in schizophrenia patients The investigators aim to develop a TMS treatment method with a fMRI-defined treatment target area where the TMS target is individually identified to maximize the TMS effects The identification method uses both the anatomical character and its functional relationship with auditory hallucination and other psychosis symptoms If the current target-identification successfully identified effective TMS target individually the treatment efficacy will be significant improved and more patients will benefit from TMS treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None